Phase IIb/III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial Bladder Cancer.
Latest Information Update: 20 Feb 2013
Price :
$35 *
At a glance
- Drugs Celecoxib (Primary)
- Indications Bladder cancer
- Focus Biomarker; Therapeutic Use
- 26 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Apr 2009 Results have been presented at the American Urological Association Annual Meeting 2009.
- 26 Apr 2009 Primary endpoint 'Time to disease recurrence' has not been met.